Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16534582 | 1.00 | KDM4E (0.34) | KDM4EALDH1A1HPGDRAB9AHIF1A | |
| SCHEMBL16534541 | 0.79 | KDM4E (0.56) | KDM4EALDH1A1HPGDRAB9AHIF1A | |
| SCHEMBL16534821 | 0.79 | PLAT (0.39) | KDM4EALDH1A1HPGDRAB9AHIF1A | |
| SCHEMBL16534925 | 0.76 | HTT (0.43) | KDM4EALDH1A1HPGDKDM5A | |
| SCHEMBL16534923 | 0.76 | HTT (0.43) | KDM4EALDH1A1HPGDKDM5A | |
| SCHEMBL16534605 | 0.74 | ALDH1A1 (0.38) | KDM4EALDH1A1HPGDRAB9AKDM5A | |
| SCHEMBL16534766 | 0.74 | PLAT (0.36) | KDM4EALDH1A1HPGDRAB9AHIF1A | |
| SCHEMBL28273367 | 0.74 | PLAT (0.36) | KDM4EALDH1A1HPGDRAB9AHIF1A | |
| SCHEMBL16534952 | 0.72 | KDM5A (0.36) | KDM4EALDH1A1HPGDKDM5A | |
| SCHEMBL16535323 | 0.72 | KDM4E (0.42) | KDM4EALDH1A1HPGDRAB9AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041474-B1 | ANTIPROLIFERATIVE COMPOUNDS | GENENTECH INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-9505767-B2 | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-3041474-A1 | ANTIPROLIFERATIVE COMPOUNDS | Genentech, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015035062-A1 | ANTIPROLIFERATIVE COMPOUNDS | GENENTECH, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM5A, KDM5B, KDM5C | KDM4E 9/4885ALDH1A1 595/4885HPGD 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.